Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Medical imaging plays a pivotal role in understanding Alzheimer’s Disease (AD) during the presymptomatic period when cognitive changes are subtle and difficult to detect. It’s important to stay current on the latest research about how these biomarkers are changing: both in terms of when (stage of the disease) and where (affected areas in the brain) and how these findings could impact your clinical development programs.
This webinar will review how novel imaging and trial designs are improving accessibility and precision in presymptomatic AD research, including:
Join us to learn how imaging biomarkers can detect Alzheimer’s decades before symptoms, supporting earlier intervention and innovative trial designs.
Date Tuesday, September 23 10:00 am ET
Presenters:
David Cash, PhD, Sr. Medical Director, Perceptive Imaging Prof. Cash is an acknowledged expert with 20 years’ experience in neuroimaging of Alzheimer’s Disease and other forms of dementia. He actively participates on various national/international committees, including DIAN, ADNI, GENFI, and has led the ISTAART Neuroimaging PIA, an organization of 1700 neuroimaging researchers working in dementia. His research focuses on identifying early signs & characterizing preclinical stages of dementias and how these changes can better inform clinical trials.
Samuel Lockhart, PhD, Sr. Scientific Director, Perceptive Imaging (Moderator) Dr. Samuel Lockhart is a neuroscientist with 20+ years’ experience investigating brain health using imaging, cognitive, and biomarker data. He has led imaging biomarker efforts in NIH ADRCs and both academic and industry clinical trials, has 90+ publications in aging and neurodegenerative disease, and is Programs Chair of the ISTAART Neuroimaging PIA. At Perceptive, Sam drives scientific strategy for imaging biomarkers in CNS clinical trials.
